Press Releases

News from the year: /2013

Oxford, UK – 18 December 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline (“GSK”) which grants GSK an optio

Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it has signed a £5 million secured loan facility agreement with its largest shareholder, the Vulpes… Read More

Read more

Interim Management Statement

Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 18 November 2013. … Read More

Read more

Oxford BioMedica: Notice of Interim Results

Results date: 29 August 2013 Oxford, UK – 23 July 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, will be announcing its interim results for the six months ended 30 June… Read More

Read more

Oxford BioMedica plc Management and Board change

Oxford, UK – 6 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that Dr Stuart Naylor will step down from the Board of Oxford BioMedica and as Chief Scientific Officer… Read More

Read more